TetraGenetics receives JDRF T1D Fund investment

JDRF T1D Fund invested an undisclosed amount in Tetragenetics Inc. (Arlington, Mass.) on May 2. Tetragenetics is developing mAbs targeting potassium channel Kv1.3 (KCNA3) to treat Type I diabetes....